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OBJECTIVES Echocardiography is the ﬁrst choice for the diagnosis of
sinus of Valsalva aneurysm (SVA). However, operator inexperience
to rare pathological patterns makes it easy to misdiagnose or fail to
diagnose SVAs.
METHODS Echocardiographic features and surgical ﬁndings of 270
Chinese SVA patients treated in the last 18 years (1995-2013) at the
Union Hospital were compared retrospectively, of which 22 cases were
rare patterns.
RESULTS The patients with a rare origin, a rare extending position
and a rare course accounted for 3.4%, 7.4% and 0.4% of 270 cases,
respectively. The three most common aneurysmal complications of
these patients with rare patterns were severe aortic regurgitation (16),
obstruction of the ventricular outﬂow tract or valvular oriﬁce (3) and
conduction disturbance (3). The origin, course, extending position
and rupture status of the SVA determined by echocardiography were
entirely consistent with surgical ﬁndings in 81.8% of 22 cases. With
the exception of one failed diagnosis of an aneurysmal wall dissection
and one misdiagnosis of a descending aortic dissection, the echocar-
diographic results of SVA complications and associated cardiovascular
lesions were also conﬁrmed.
CONCLUSIONS Echocardiography can accurately diagnose SVAs with
different rare pathological patterns by identifying distinguishing
features. However, for several conditions, echocardiography alone
could not accurately identify the origin or course of the aneurysm or
deﬁne its relationship to adjacent structures. Therefore, combining
different imaging techniques, such as CT angiography and aortic
angiography, is recommended.GW26-e1532
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OBJECTIVES Thoracic aortic aneurysm and dissection (TAAD) has
become a clinical emergency situation that threats human life seri-
ously during past decades in China. Hypertension and hyper-
lipoidemia are considered as the high risks for TAAD. Genetic studies
have revealed that mutations on certain genes might be the real cause
for inherited TAAD, such as mutations on FBN1, TGFBR1/2, and
SMAD3. Next-generation sequencing is now widely used to ﬁnd
possible genetic changes for familial TAAD patients and to help
them reducing mortality events. However, most next-generation
sequencing data requires professional bioinformatics analysis. More-
over, most patients have been proved without any known familial
risks for TAAD. Limited genetic associations are found among spo-
radic TAAD individuals. This study sought to apply a targeted next-
generation sequencing panel with associated genetic information to
2 TAAD families and 8 sporadic TAAD individuals to unravel the
potential genetic connections among sporadic TAAD.
METHODS We applied a targeted next-generation sequencing panel
for 4813 genes including most reported genes associated with TAAD.
Screens were performed in 2 families, both of which were with one
member having TAAD, and 8 unrelated individuals with TAAD.
Sequencing data was analyzed based on the information provided
in the panel. Extensive cardiological examination was performed,
which included physical examination, electrocardiography, and
echocardiography.
RESULTS Two potential novel variants on FBN1 and MMP12 respec-
tively were indentiﬁed in one family. Those two variants were only
found in the proband, not in any other family members. Among theother family and 8 sporadic TAAD individuals, neither 2 potential
novel variants nor any other reported mutations were detected.
CONCLUSIONS Our ﬁnding suggests that next-generation sequencing
panel targeted on 4813 genes is a promising tool for early genetic
diagnosis of TAAD from known genes. With all the information in the
panel, clinicians may provide genetic consultations within days.
Despite the advantages above, few associations between TAAD in-
dividuals in our study implies that entire exon sequencing on larger
population may provide more information for targeted sequencing
panel and reveal the underlying genetic pathogenesis for TAAD.
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OBJECTIVES To explore the relationship between CYP4F2 gene
polymorphism and coronary heart disease (CHD) in a Chinese Han
population.
METHODS We selected 440 CHD patients and 440 control subjects to
perform a case - control study. Four SNPs (rs2108622, rs3093100,
rs3093105 and rs3093135) in CYP4F2 gene were genotyped using po-
lymerase chain reaction - restriction fragment length polymorphism
(PCR - RFLP) methods. The genotype and haplotype distributions
were compared between the case and the control group.
RESULTS We found both rs2108622 and rs3093105 in CYP4F2 gene
were associated with the risk for CHD (P <0.01). Haplotype analysis
indicated that GGGT haplotype consisted by rs2108622-rs3093100-
rs3093105-rs3093135 was associated with CHD risk (OR ¼ 4.367, 95%
CI: 2.241w 8.510; P < 0.001), but GGTA haplotype was associated with
decreased risk for CHD (OR ¼ 0.450, 95%CI: 0.111 w 0.777; P <0.001).
CONCLUSIONS CYP4F2 gene polymorphisms were associated with
the risk of CHD in Chinese population.
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Serum Level of Fibroblast Growth Factor 21 is Independently Associated
with Acute Myocardial Infarction
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OBJECTIVES Fibroblast growth factor 21 (FGF21) has been described a
metabolic hormone critical for glucose and lipid metabolism. Previ-
ously, high levels of FGF21 were observed in patients with coronary
heart disease and non-acute myocardial infarction (non-AMI). In this
study, we investigated the changes in FGF21 levels in Chinese patients
with AMI.
METHODS We enrolled 55 patients in whom AMI (including
ST-segment and non-ST-segment elevation, within 24 h after admis-
sion) was diagnosed between March and August 2013 at the Ministry
of Health, Beijing Hospital. The control group included 45 patients
with chest pain without creatine kinase (CK), creatine kinase- MB
(CK-MB) and Troponin T (TNT) elevation. The patients in control
group were also diagnosed coronary heart disease by Coronary angi-
ography. We used ELISA to measure circulating FGF21 levels in 55
AMI patients and 45 non-AMI control patients on the 1st day after
syndrome onset. All patients were followed-up within 30 days.
RESULTS FGF21 levels in AMI patients were signiﬁcantly higher than
those in non-AMI controls (0.25 (0.16-0.34) vs. 0.14 (0.11-0.20) ng/mL,
P < 0.001). FGF21 levels reached the maximum within approximately
24 h after the onset of AMI and remained at high for 7 days, and
the FGF21 level (OR: 16.93; 95% conﬁdence interval (CI): 2.65-108.05;
P ¼ 0.003) was identiﬁed as an independent factor associated with
the presence of AMI. On the 7th day, FGF21 levels were signiﬁcantly
higher in the patients who subsequently developed re-infarction
within 30 days than in the patients who did not develop re-infarction
(with vs. without re-infarction: 0.45 (0.22-0.64) vs. 0.21 (0.15-0.29)
ng/mL, P ¼ 0.014).
CONCLUSIONS The level of serum FGF21 is independently associ-
ated with the presence of AMI in Chinese patients. High FGF21
levels might be related to the incidence of re-infarction within 30
days after onset.
